News | April 02, 2008

Corgenix Signs Deal to Automate Platelet Test Kit Processing

April 3, 2008 - Corgenix Medical Corp. has entered into an agreement with Randox Laboratories, a UK-based diagnostic company, in a partnership designed to expand the processing technology and distribution network of the Corgenix AspirinWorks platelets test kit product.

Under the terms of the agreement, the companies will collaborate in adapting the Corgenix AspirinWorks test to a format compatible with automated chemistry analyzers. The AspirinWorks test will be manufactured at Randox facilities in the UK, and the two companies will share global distribution rights.

According to Douglass Simpson, Corgenix President and CEO, "a key factor in the future success of the AspirinWorks product will be automation," and that he hopes this alliance will "result in a successful launch of the new product format next year."

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's aspirin therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the current AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.

For more information: www.corgenix.com and www.randox.com

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init